Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $972.65M
- Beta
- 0.00
Volume 0.28M
Average 0.41M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
No data available for this stock.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
LB Pharmaceuticals Inc Common Stock NASDAQ:LBRX | $1.39B | $43.01 | Not rated | -21.4 | +153.14% |
GH Research PLC NASDAQ:GHRS | $1.31B | $19.10 | Not rated | -23.8 | +32.87% |
Rapport Therapeutics, Inc. Common Stock NASDAQ:RAPP | $1.25B | $26.15 | Not rated | -16.2 | -6.16% |
Contineum Therapeutics, Inc. Class A Common Stock NASDAQ:CTNM | $348.58M | $9.86 | Not rated | -7.5 | -17.03% |
MapLight Therapeutics, Inc. NASDAQ:MPLT | $308.98M | $7.25 | Not rated | -2.8 | -55.82% |
Vanda Pharmaceuticals Inc. NASDAQ:VNDA | $241.27M | $3.99 | Not rated | -1.4 | -28.79% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $80.59M | $0.43 | Not rated | -1.2 | -87.42% |
Continue the stock analysis
Jump to another research area for this company.